Mathavan S, Tam Y, Mustaffa K, Tye G
Front Immunol. 2025; 16:1536569.
PMID: 40034705
PMC: 11873091.
DOI: 10.3389/fimmu.2025.1536569.
Xiao F, Shen X, Tang W, Yang D
JACS Au. 2025; 5(2):550-570.
PMID: 40017777
PMC: 11863167.
DOI: 10.1021/jacsau.4c01274.
Zhang G, Yan S, Liu Y, Du Z, Min Q, Qin S
Bioanalysis. 2025; 17(4):261-276.
PMID: 39895280
PMC: 11864318.
DOI: 10.1080/17576180.2025.2459528.
Zhang K, Nie Q, Li M, Chen X, Zhong L, Dai T
Nucleic Acids Res. 2025; 53(3).
PMID: 39883012
PMC: 11780864.
DOI: 10.1093/nar/gkaf039.
Tang D, He S, Yang Y, Zeng Y, Xiong M, Ding D
Nat Commun. 2025; 16(1):923.
PMID: 39843440
PMC: 11754784.
DOI: 10.1038/s41467-025-56219-9.
Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma.
Fu X, Huang J, Chen X, Xie D, Chen H, Liang Z
Theranostics. 2025; 15(1):103-121.
PMID: 39744222
PMC: 11667235.
DOI: 10.7150/thno.99588.
Recent Advances and Prospects of Nucleic Acid Therapeutics for Anti-Cancer Therapy.
Lee M, Lee M, Song Y, Kim S, Park N
Molecules. 2024; 29(19).
PMID: 39407665
PMC: 11477775.
DOI: 10.3390/molecules29194737.
Lysosome-targeting chimeras containing an endocytic signaling motif trigger endocytosis and lysosomal degradation of cell-surface proteins.
Fang T, Zheng Z, Li N, Zhang Y, Ma J, Yun C
Chem Sci. 2024; .
PMID: 39391383
PMC: 11459673.
DOI: 10.1039/d4sc05093b.
Transferrin receptor targeting chimeras for membrane protein degradation.
Zhang D, Duque-Jimenez J, Facchinetti F, Brixi G, Rhee K, Feng W
Nature. 2024; 638(8051):787-795.
PMID: 39322661
PMC: 11839386.
DOI: 10.1038/s41586-024-07947-3.
Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis.
Zhou P, Zhang S, Li L, Zhang R, Guo G, Zhang Y
Theranostics. 2024; 14(13):4983-5000.
PMID: 39267779
PMC: 11388081.
DOI: 10.7150/thno.98467.
Versatile Split-and-Mix Liposome PROTAC Platform for Efficient Degradation of Target Protein .
Song C, Jiao Z, Hou Z, Xing Y, Sha X, Wang Y
JACS Au. 2024; 4(8):2915-2924.
PMID: 39211615
PMC: 11350581.
DOI: 10.1021/jacsau.4c00278.
An Aptamer Glue Enables Hyperefficient Targeted Membrane Protein Degradation.
Zhang G, Zhang C, Fu T, Tan W, Wang X
JACS Au. 2024; 4(8):2907-2914.
PMID: 39211579
PMC: 11350568.
DOI: 10.1021/jacsau.4c00260.
A plug-and-play monofunctional platform for targeted degradation of extracellular proteins and vesicles.
Yao S, Wang Y, Tang Q, Yin Y, Geng Y, Xu L
Nat Commun. 2024; 15(1):7237.
PMID: 39174543
PMC: 11341853.
DOI: 10.1038/s41467-024-51720-z.
Evolution of a bispecific G-quadruplex-forming circular aptamer to block IL-6/sIL-6R interaction for inflammation inhibition.
Yao L, Wang L, Liu S, Qu H, Mao Y, Li Y
Chem Sci. 2024; 15(32):13011-13020.
PMID: 39148786
PMC: 11323322.
DOI: 10.1039/d4sc02183e.
Targeted degradation of membrane and extracellular proteins with LYTACs.
Li Y, Yang Y, Zhang R, Ge R, Xie S
Acta Pharmacol Sin. 2024; 46(1):1-7.
PMID: 39103530
PMC: 11696130.
DOI: 10.1038/s41401-024-01364-y.
Structure-based investigation of a DNA aptamer targeting PTK7 reveals an intricate 3D fold guiding functional optimization.
He A, Wan L, Zhang Y, Yan Z, Guo P, Han D
Proc Natl Acad Sci U S A. 2024; 121(29):e2404060121.
PMID: 38985770
PMC: 11260122.
DOI: 10.1073/pnas.2404060121.
Expanding the horizons of targeted protein degradation: A non-small molecule perspective.
Huang X, Wu F, Ye J, Wang L, Wang X, Li X
Acta Pharm Sin B. 2024; 14(6):2402-2427.
PMID: 38828146
PMC: 11143490.
DOI: 10.1016/j.apsb.2024.01.010.
Directed evolution of genetically encoded LYTACs for cell-mediated delivery.
Yang J, Yamada-Hunter S, Labanieh L, Sotillo E, Cheah J, Roberts D
Proc Natl Acad Sci U S A. 2024; 121(13):e2320053121.
PMID: 38513100
PMC: 10990137.
DOI: 10.1073/pnas.2320053121.
Multivalent Aptamer-Based Lysosome-Targeting Chimeras (LYTACs) Platform for Mono- or Dual-Targeted Proteins Degradation on Cell Surface.
Duan Q, Jia H, Chen W, Qin C, Zhang K, Jia F
Adv Sci (Weinh). 2024; 11(17):e2308924.
PMID: 38425146
PMC: 11077639.
DOI: 10.1002/advs.202308924.
Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview.
Liu X, Cheng Y, Mu Y, Zhang Z, Tian D, Liu Y
Front Immunol. 2024; 15:1328145.
PMID: 38298192
PMC: 10828056.
DOI: 10.3389/fimmu.2024.1328145.